Sequence matters: Total body irradiation (TBI)‐based myeloablative conditioning with post‐transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus TBI
暂无分享,去创建一个
J. Briones | R. Martino | S. Miqueleiz | S. Novelli | J. Portos | A. Esquirol | A. Caballero | G. Sancho | I. García-Cadenas | A. Garrido | G. Oñate | J. Sierra | S. Redondo | S. Saavedra | C. Moreno | Jordi López-Pardo | Miguel Arguello-Tomás | Antonio Vila | Miguel Arguello-Tomas
[1] A. Ganser,et al. Retrospective Comparison between 12-Gray and 8-Gray Total Body Irradiation (TBI) before Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Lymphoblastic Leukemia in First Complete Remission , 2021, Blood.
[2] E. Leifer,et al. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. , 2021, Transplantation and cellular therapy.
[3] S. Montoto,et al. How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. , 2020, Blood advances.
[4] An Liu,et al. The safety and efficacy of a novel hypo-fractionated total marrow and lymphoid irradiation before allogeneic stem cell transplantation for lymphoma and acute leukemia , 2020, Clinical and translational radiation oncology.
[5] N. Kröger,et al. Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia , 2020, Leukemia.
[6] J. Briones,et al. Incorporating posttransplant cyclophosphamide-based prophylaxis as standard-of-care outside the haploidentical setting: challenges and review of the literature , 2019, Bone Marrow Transplantation.
[7] C. de Miguel,et al. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[8] M. Perales,et al. Comparison of high doses of total body irradiation in myeloablative conditioning prior to hematopoietic cell transplantation. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] S. Montoto,et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors , 2019, Bone Marrow Transplantation.
[10] A. Viswabandya,et al. Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants , 2019, European journal of haematology.
[11] R. Storb,et al. Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms , 2019, Haematologica.
[12] H. Eich,et al. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. , 2018, The Lancet. Haematology.
[13] J. Ritz,et al. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[14] M. Labopin,et al. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT , 2018, Journal of Hematology & Oncology.
[15] Shannon R. McCurdy,et al. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide , 2017, Haematologica.
[16] R. Storb,et al. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. , 2016, Blood.
[17] W. Wood,et al. Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[18] H. Greinix,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .
[19] Tao Wang,et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[20] W. Hiddemann,et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. , 2012, The Lancet. Oncology.
[21] M. Horowitz,et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. , 2012, Blood.
[22] Michael Boeckh,et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.
[23] B. Cho,et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[24] Allen R. Chen,et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[25] G. Mufti,et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. , 2006, Blood.
[26] J. Pérez-Simón,et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning , 2003, Bone Marrow Transplantation.
[27] E D Thomas,et al. 1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.
[28] P. Neiman,et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. , 1977, Blood.
[29] J. Briones,et al. Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease , 2017, Bone Marrow Transplantation.
[31] S. Brunet,et al. Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission , 2008, Bone Marrow Transplantation.
[32] H. Deeg,et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis , 2006, Leukemia.